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Hepatitis C virus (HCV) is a blood-borne pathogen that causes widespread chronic liver disease 
(1). In an article in the current issue of Hepatology, Perin et al. identify flunarizine, a clinically 
approved drug for treating migraine, as an inhibitor of specific HCV genotypes (Fig. 1A). 
Leveraging several experimental approaches, the authors demonstrate that fusion of viral and 
host-cell membranes during viral entry is the step that is susceptible to flunarizine inhibition. 
Determinants of susceptibility to this and related drugs including fluphenazine, pimozide, and 
trifluoperizine (Fig. 1B) reside in the E1 and E2 envelope glycoproteins of HCV.  These findings 
suggest a cost-efficient potential anti-HCV therapeutic strategy and shed light on the mechanism 
of HCV cell entry. 
 
HCV is an enveloped positive-sense single-stranded RNA virus from the hepacivirus genus in 
the Flaviviridae family. In the bloodstream of infected patients it travels in association with 
lipoprotein particles. HCV is highly hepatotropic and follows a complex entry pathway reliant on 
multiple host entry factors (2). Following attachment and trafficking to tight junctions in 
polarized hepatocytes, the virus is internalized and fusion of the viral and endosomal membranes 
proceeds by mechanism dependent on the reduced pH of the endosomal lumen. Once HCV 
genome is delivered to the cytoplasm, a single polyprotein is translated and processed into three 
structural and seven non-structural proteins. Genome replication and egress of newly formed 
virions complete the lifecycle. Several recently approved anti-HCV drugs target viral polyprotein 
processing and genome replication (3).  
 
HCV E1 and E2 are the two envelope glycoproteins required for cellular attachment and 
membrane fusion. E1 and E2 form stable heterodimers and are anchored in the viral membrane 
by their C-terminal transmembrane domains. Recent structural studies revealed that HCV E1 and 
E2 proteins have molecular architectures distinct from the envelope proteins of other viruses 
from other genera within the Flaviviridae family (4-6). E2 contains the determinants of 
attachment while E1 has been proposed to contain the determinants of fusion. However, the 
molecular trajectory leading to membrane fusion is not fully understood due in part to the lack of 
a complete three-dimensional structure of the E1/E2 heterodimer.  
 
More than a decade before the discovery of HCV, flunarizine was developed as a calcium 
antagonist with potential applications in treatment of vascular disorders (7). In the 1980s it found 
widespread use as an effective anti-migraine therapeutic and is still used in this capacity in 
Canada and continental Europe today. While the structural basis of flunarizine binding and 
inhibition of voltage-gated calcium channels is not known, flunarizine acts to inhibit calcium 
influx into smooth muscles cells preventing constriction of blood vessels and thus helps improve 
blood flow to the brain to combat the pathophysiology of migraine. 
 
Perin et al. identified flunarizine as a submicromolar HCV inhibitor in a whole lifecycle screen 
of a library of clinically approved drugs. They confirmed this finding in assays using primary 
human hepatocytes, humanized reporter mice, and in vitro grown hepatic organoids. Using 
chimeric viruses they showed that susceptibility to flunarizine and related compounds varies 
widely between HCV subtypes and is encoded in the E1 and E2 proteins. Isolation of flunarizine-
resistant mutants allowed determination of specific residues necessary for inhibiting the viral 
lifecycle. These included M267V and Q289H in E1, M405T in E2 and I757T in p7. 
Interestingly, M267, a key determinant of flunarizine susceptibility, is limited to the susceptible 
genotype, genotype 2a – a result that neatly dovetails observations obtained with chimeric 
viruses.  
 
In elegant time of addition experiments Perin et al. demonstrated that flunarizine inhibition 
occurs at the membrane fusion step of cell entry. In these experiments individual steps of the 
entry pathway were controlled by temperature and pH shifts. Flunarizine showed a unique ability 
to block viral lifecycle (assayed using a luciferase reporter, an indirect readout) when added 
during the low-pH incubation that triggers fusion. This result was strengthened by the direct 
observations obtained by infecting hepatic organoids with viruses carrying fluorescently labeled 
membranes. While HCV association with tight junction markers and endocytic pathway markers 
was unaffected by flunarizine, the increase in fluorescence that follows mixing of viral and host 
membranes was strongly inhibited. 
 
Molecular mechanism underlying flunarizine fusion inhibition remains unclear. Lack of effect of 
calcium chelators and unrelated calcium channel inhibitors, such as nickel (Ni
2+
) ions, suggests 
that calcium flux inhibition is not required for fusion arrest. Likewise, membrane stiffness and 
cholesterol content appeared unaffected by flunarizine and the related compounds. Additionally, 
similar genotype specificities and shared resistance mutants of the flunarizine-like compounds 
argue against an indirect mode of action. Instead, it is possible that genotype 2 viruses use a 
unique host cofactor during entry and that flunarizine inhibits that interaction. Alternatively, 
flunarizine may directly stabilize the genotype 2 envelope proteins in a fusion incompetent 
conformation. Given the hydrophobic nature of these compounds, it is possible that they share a 
common binding site on the E1/E2 dimer despite their different chemical structures. Further 
investigation into the mechanism of inhibition will shed light on both the clinical applicability of 
these scaffolds and on the HCV entry pathway. 
 
The findings reported by Perin et al. are significant because targeting of viral fusion step has 
been underexplored for its therapeutic potential. So far, mechanism-based fusion inhibitors have 
been developed for class I fusion proteins, such as those of HIV (8), and several approaches for 
inhibiting class II fusion proteins have been advanced including broad specificity drugs affecting 
membrane stiffness (9). Discovery of the antiviral activity of flunarizine adds membrane fusion 
as a new target to the anti-HCV repertoire. Although flunarizine is only effective against HCV 
genotype 2, it may offer a cost-effective complement to the currently available treatments, which 
will remain unaffordable to a significant fraction of the infected population for some time. 
Moreover, flunarizine may serve as an invaluable molecular platform for the design of more 
broadly active and more potent HCV entry inhibitors. Such design efforts would be greatly aided 
if the structure of the flunarizine binding pocket on HCV E1/E2 could be determined. 
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Figure Legend 
 
Fig. 1. The chemical structure and activity of flunarizine. (A) Flunarizine is a large hydrophobic 
fluorinated piperazine derivative used in the prophylaxis of migraine. Its activity is based on 
blocking calcium influx into vascular smooth muscle. In an article in the current issue of 
Hepatology, Perin et al. report that flunarizine also blocks the HCV lifecycle at the membrane 
fusion step. (B) Fluphenazine, pimozide, and trifluoperazine form a subset of related calcium 
antagonists that show similar ability to inhibit HCV entry as flunarizine and are likely to share 
the inhibitory mechanism of flunarizine. 
 
